Purpose: To evaluate the safety of live attenuated influenza vaccine (LAIV) in children 2 through 17 years of age.
found that LAIV remains effective, 5, 6 and the vaccine continues to be administered in Canada, the United Kingdom, 5 and elsewhere. 6 LAIV remains licensed for use in the USA, 1, 7 and ACIP recommendations could change to support LAIV use in the future.
The safety of LAIV in children has been evaluated in pre-licensure and post-licensure studies; commonly reported symptoms have included nasal congestion, headache, fever, vomiting, and abdominal pain. [8] [9] [10] [11] [12] Several studies have found an age-dependent effect of LAIV on wheezing, with asthma and medically attended wheezing reported in younger 10, 13 but not older 10, [13] [14] [15] [16] [17] children. Consequently, LAIV is not licensed for children <24 months of age, is contraindicated in children 2 through 4 years of age with asthma or recurrent wheezing, and has precautions regarding use in children ≥5 years of age with asthma. 1, 7 Aside from an association with asthma and wheezing in young children, no serious adverse events have been attributed to LAIV in randomized [8] [9] [10] [11] [12] 14, 15 or observational 16, 17 studies. Additionally, no unexpected serious adverse event reporting patterns have been found following LAIV in the Vaccine Adverse Events Reporting System (VAERS). 18, 19 Although existing LAIV safety data are reassuring, prior studies have certain limitations. Randomized trials of LAIV have not included adequate sample size to examine rare adverse events, [8] [9] [10] [11] [12] and VAERS data cannot be used for formal hypothesis testing. 20 The objective of this investigation was to examine LAIV safety in a large cohort of children 2 through 17 years of age.
2 | METHODS
| Study setting and population
This study was conducted in the Vaccine Safety Datalink (VSD), a collaboration between the Centers for Disease Control and Prevention (CDC) and 9 large integrated health care organizations (referred to as "sites"). [21] [22] [23] The study population included all children 2 through 17 years of age with continuous health insurance enroll- of LAIV receipt, and children only contributed data for influenza seasons during which they received LAIV and were age eligible. This study period was chosen because the investigation focused exclusively on trivalent LAIV; quadrivalent LAIV replaced the trivalent vaccine beginning with the 2013 to 2014 season. 24 The Pediatric
Medical Complexity Algorithm was used to define health status;
using this algorithm, a condition such as asthma would be considered a non-complex chronic condition. 25 The human subjects review board at each site approved the study; informed consent was not required.
| Study design
Self-controlled case series (SCCS) analyses were used to examine the risk of adverse events following LAIV vaccination. [26] [27] [28] [29] In SCCS analyses, which is a cases-only design, the incidence rate of adverse events in a risk period following vaccination is compared with the rate in control periods before and after the risk period. [26] [27] [28] [29] Preliminary analyses were based upon diagnosis codes from electronic health records. Any adverse event with a positive signal in preliminary analyses underwent manual medical record review, and SCCS analyses were subsequently repeated using only cases confirmed by manual review.
| Vaccine exposure
Electronic health record data were used to identify all children in the study population who received LAIV. Children may have received LAIV in multiple influenza seasons; LAIV doses given in different influenza seasons were treated as independent exposures. Children may have received 2 LAIV doses within an influenza season; 24, 30 only the first LAIV dose per season was included in analyses. The study focused on trivalent LAIV safety; monovalent A(H1N1)pdm09 LAIV and quadrivalent LAIV were not included in analyses. Children may have received other vaccines on the same day as LAIV.
| Potential adverse events following immunization
Safety data from pre-licensure and post-licensure trials, [8] [9] [10] [13] [14] [15] LAIV package inserts, 31 and reports to VAERS 18 were used to select the adverse events examined. Consistent with prior vaccine safety studies, [32] [33] [34] we selected potential adverse events which were (1) biologically plausible to occur following vaccination; (2) serious enough to result in a medical encounter; and (3) thought to occur relatively
KEY POINTS
• Although existing data regarding the safety of live attenuated influenza vaccine are reassuring, prior studies have not had adequate sample size to examine rare adverse events.
• The safety of trivalent live attenuated influenza vaccine was evaluated in more than 396 000 children and adolescents.
• Anaphylaxis and syncope were significantly associated with live attenuated influenza vaccine, although occurrences were rare.
• These data provide reassurance regarding continued use of live attenuated influenza vaccine. For 3-digit ICD-9-CM codes, all 4-digit and 5-digit codes with the same first 3 digits were included; for 4-digit codes, all 5-digit codes with the same first 4 digits were included.
b
The day of vaccination was defined as Day 0.
c To ensure that a visit was not for follow-up of a previously diagnosed condition, the event was required to be the first in a pre-specified time period.
d A 5-digit code (695.13), more specific for Stevens-Johnson syndrome, has been added to ICD-9-CM, but was not in use early in the study period; therefore, the 4-digit code was used.
acutely following vaccination. Adverse events were defined by International Classification of Diseases, 9 th Revision, Clinical Modification (ICD-9-CM) diagnosis codes; ICD-10-CM codes were not yet in use.
Most adverse events were defined using multiple codes, because in clinical practice, several different ICD-9-CM codes can be used for the same condition.
Eighteen potential adverse events were examined (Table 1) . For each adverse event, we identified a risk period (the days following vaccination during which an individual was considered at risk for a particular adverse event) and the medical setting of the encounter. For most adverse events, we restricted encounters to inpatient and emergency department (ED) settings, because ICD-9-CM diagnosis codes from outpatient settings typically have poor accuracy for identifying incident cases of serious adverse events. 35, 36 Guillain-Barré syndrome, venous thromboembolism, and thrombocytopenia were examined in all settings (inpatient, ED, outpatient), as these conditions are rare in children. Because angioneurotic edema and other non-anaphylactic allergic reactions may not result in inpatient or ED encounters, we examined this adverse event group, and each individual ICD-9-CM code within the group, in outpatient as well as inpatient and ED settings. To ensure that encounters were not for follow-up of previously diagnosed conditions, we required that events be the first in a prespecified time period (Table 1 , last column).
| Manual review of electronic health records
Any adverse event with a positive signal in preliminary analyses underwent manual medical record review to confirm case status. This step was necessary because diagnosis codes from electronic health records do not always represent true incident cases. 35, 36 We defined a positive signal as (1) a statistically significant elevated risk of an adverse event following LAIV; or (2) a point estimate of risk exceeding a risk ratio of 2.0, even if not statistically significant. Using a standardized chart abstraction form, trained abstractors reviewed provider encounter notes of relevant visits. Prevalent cases, "ruled out" cases, and cases definitively attributed to another cause 37 (such as anaphylaxis after peanut consumption in someone known to be peanut-allergic) were excluded after manual record review.
Syncope was one of the adverse events for which manual medical record review was performed. Because it was not feasible to review all 543 syncope cases, a sample of 200 cases were reviewed: all syncope cases occurring in the risk window were reviewed, and a random sample of cases from the control period. The case confirmation rate was estimated from the sampled cases and then applied to the nonreviewed cases using multiple imputation as a means of addressing the uncertainty of the confirmation rate.
| Analytic methods
SCCS methods [26] [27] [28] [29] were used to assess the risk of adverse events following LAIV. The incidence rate of adverse events in a risk period following vaccination was compared with the incidence rate in control periods before and after the risk period, with each individual acting as his or her own control. The risk period for each adverse event is
shown in Table 1 . The control period was defined as all person-time within a given influenza season that was not within the risk period. 38 The 14 days immediately preceding LAIV vaccination were excluded from the control period, because adverse event rates immediately preceding vaccination are known to be lower than the baseline rate of disease. 39 Observation time was censored when an individual received monovalent A(H1N1)pdm09 LAIV or a second dose of trivalent LAIV.
Conditional Poisson regression analyses were used to calculate incident rate ratios (IRRs) for each adverse event group. Because vaccination and baseline disease incidence rates are seasonal (ie, likely to vary over time), we adjusted for calendar month of the adverse event. Unexposed cases (ie, individuals who did not receive LAIV that influenza season) were also included in adjusted analyses to control for changes in baseline disease incidence rates over calendar time.
After preliminary analyses were completed, manual medical record review was performed, and conditional Poisson analyses were repeated using only cases confirmed by manual medical record review.
Our primary analyses included all LAIV doses, whether or not other vaccines were received on the same day. In secondary analyses, we limited analyses to LAIV doses received with no other same-day vaccines. All analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC).
| Statistical power
In the VSD during the study period, 590 018 doses of trivalent LAIV were given to children 2 through 17 years of age. Based on 80% power and a significance level of 0.05, a study with this sample size was powered to detect an IRR of 1.2 for a 14-day risk window and 1.1 for a 42-day risk window for a disease with a background rate of 100 per 100 000 person-years. For a disease with a background rate of 1 per 100 000 person-years, the study was powered to detect an IRR of 4.8 for a 14-day risk window, and 3.3 for a 42-day risk window. Results from manual medical record review are presented in Table 4 . As shown, a number of cases were excluded because the cases could be clearly attributed to another etiology. 37 For example, we 
| Risk estimates using adverse events confirmed by medical record review
For the 5 adverse event groups with a positive signal in preliminary analyses, risk estimates were recalculated using only confirmed cases.
As shown in Table 5 , anaphylaxis and syncope were significantly associated with LAIV exposure, whereas adverse effect of drug, StevensJohnson syndrome, and respiratory failure were not. b Health status within the 12 months prior to receipt of LAIV was determined using a previously published algorithm, the Pediatric Medical Complexity Algorithm. 
| Secondary analyses
All pre-specified adverse events were examined in secondary analyses, in which the study cohort was restricted to LAIV recipients who received no other vaccines on the same day. Results were similar to primary analyses, and no other significant associations were detected.
| DISCUSSION
Using well-established methods [26] [27] [28] in a multi-site vaccine safety surveillance network, [21] [22] [23] the safety of trivalent LAIV was examined in more than 396 000 children and adolescents who received more than 590 000 doses of LAIV over a 10-year period. Based on cases confirmed by manual medical record review, 2 adverse events, anaphylaxis and syncope, were significantly associated with LAIV, although occurrences were rare. Anaphylaxis and syncope are known vaccine-associated adverse events, [40] [41] [42] which can be medically managed when they occur to minimize any long-term consequences. 43 These additional data regarding the safety profile of LAIV should provide reassurance for countries using LAIV, 5, 6 as well as countries such as the United States that could recommend LAIV in the future.
Anaphylaxis was significantly associated with LAIV in the current study, with a single case occurring soon after LAIV vaccination in a 3-year-old with pre-existing egg allergy. It is plausible that vaccineassociated anaphylaxis occurs more commonly among individuals with allergic disease. 40 Although LAIV contains trace amounts of the egg white protein ovalbumin, 31 several open-label trials have found LAIV safe in egg-allergic patients; in these studies, small numbers of children had mild, resolving reactions that could have been allergic in nature. 44, 45 In a recent VSD study, using anaphylaxis cases validated by manual medical record review, the rate of anaphylaxis following any vaccine was 1.3 per million vaccine doses, and all those with anaphylaxis recovered. 40 In this context, it is important to note that the absolute rate of confirmed anaphylaxis following LAIV in the current study (1.7 per million doses) was similar to the published rate following other vaccines. 40 Consequently, this finding supports the The number of events in risk and control periods were based upon ICD-9-CM diagnosis codes from electronic health records, among subjects who had received LAIV at any time during the influenza season.
b Self-controlled case series analyses, adjusted for seasonality; unexposed cases (ie, individuals who did not receive LAIV in a given influenza season) were also included in adjusted analyses to control for changes in baseline disease incidence rates over calendar time. The incident rate ratio was noted as not estimated (NE) if there were no observed events among the vaccine recipients in the risk window.
premise, articulated in ACIP influenza vaccine recommendations 1 and a recent review, 46 that hypersensitivity reactions following influenza vaccines are not necessarily related to the trace amounts of egg protein found in influenza vaccines.
Syncope and near-syncope are also known to occur following vaccination, particularly in adolescents, 41, 42 and we found an association between LAIV and syncope. While post-vaccination syncope typically occurs without long-term consequences, serious injuries such as head injuries from falls during syncopal episodes can occur. 47 The pain and anxiety associated with receiving an injection are thought to trigger syncope, and 4 of the 5 cases of syncope in the current study received injectable vaccines at the same time as LAIV. However, 1 case of syncope occurred in an individual who received LAIV only; it is possible that anxiety, discomfort, or pain with intranasal administration triggered syncope in this individual. To help prevent syncope-related injuries, the ACIP recommends that vaccine recipients be seated or laying down during vaccination and be observed for 15 minutes post-vaccination, 43 although this often does not occur in routine practice. 48 Several additional findings are important to highlight. We did not find a significantly increased rate of asthma encounters in ED and inpatient settings following LAIV. While this is reassuring, it is important to note the vast majority (91.7%) of patients in our study population did With the exception of syncope, all cases from risk and control periods were reviewed; for syncope, a total of 200 cases were reviewed, including all n = 11 cases in the risk window and a sample of n = 189 cases in the control period.
b Self-controlled case series analyses, adjusted for seasonality; the incident rate ratio was denoted as not estimated (NE) if there were no observed events among the vaccine recipients in the risk window. Because not all syncope cases from the control period underwent manual medical record review, the case confirmation rate was estimated from sampled cases, and then applied to non-reviewed cases using multiple imputation to generate the incident rate ratio and confidence interval. Medical record not available for review (n = 17); syncope during or while observing medical procedure, eg, blood draw (n = 16); no syncope (n = 9); seizure (n = 5); follow-up of prior syncopal episode (n = 6); trauma (n = 2); exercise (n = 2); prior to vaccination (n = 1); breath-holding (n = 1); severe anemia (n = 1); helium inhalation (n = 1); smoke inhalation (n = 1); anaphylaxis (n = 1); adrenal insufficiency (n = 1); arrhythmia (n = 1) 135 Anaphylaxis 21 Anaphylaxis attributed to nut exposure, in someone known to be nut-allergic (n = 5); medical record not available for review (n = 4); local reaction attributed to injection (n = 2); anaphylaxis attributed to intravenous contrast (n = 1); anaphylaxis attributed to insect sting (n = 1) With the exception of syncope, all cases from risk and control periods were reviewed; for syncope, a total of 200 cases were reviewed, including all n = 11 cases in the risk window and a sample of n = 189 cases in the control period.
b Multiple ICD-9-CM codes comprised the non-anaphylactic allergic reactions group; each was examined individually in SCCS analyses; adverse effect of drug was the only ICD-9-CM code which was significantly elevated. Additionally, not all syncope cases underwent manual review; this could have influenced results if the reviewed cases were not representative of all cases of syncope in the study population. Although the sample size was large (n = 590 018), the study may not have been adequately powered to detect very rare but serious adverse events such as Guillain-Barré syndrome. This study focused exclusively on trivalent LAIV, which has been replaced by a quadrivalent vaccine. 24 While this is a limitation, trivalent and quadrivalent LAIV are manufactured using the same processes and have very similar compositions, 7, 31 suggesting that safety findings regarding trivalent LAIV are directly relevant to the quadrivalent formulation. Finally, SCCS methods are susceptible to time-varying confounding. 28 While we controlled for month in our analyses, it is possible that our results were confounded by unmeasured factors which changed over the observation period.
In conclusion, the safety of trivalent LAIV was evaluated in a large cohort of children and adolescents; anaphylaxis and syncope were rarely but significantly associated with vaccination. These data provide reassurance regarding vaccine use in countries that continue to recommend LAIV.
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